Neuland Laboratories Limited — PPTs, 15-05-2025: Investor Presentation

1. Financial Highlights:

Neuland Labs reported total income of Rs. 1,497.3 Cr for FY25, down 4.7% YoY, with Q4 revenue at Rs. 335.8 Cr (-14% YoY). EBITDA declined 27.7% to Rs. 342.8 Cr, with margins contracting to 22.9% from 30.2% last year; Q4 EBITDA margin fell to 17.3%. PAT dropped 13.4% YoY to Rs. 259.4 Cr for FY25, with Q4 PAT at Rs. 27.7 Cr (-59%). Free cash flow remained strong at Rs. 111 Cr, despite higher capex of Rs. 206.4 Cr. Net debt position improved substantially to a net cash balance of Rs. (228.7) Cr. Working capital days eased slightly to 107 in Q4.

2. Strategic Initiatives & Growth Drivers:

The company is pivoting from Prime APIs to higher-margin Specialty and CMS segments, accounting for over 50% of revenues. Peptide APIs, focused on chronic diseases, are a core growth driver; capex of Rs. 254 Cr is allocated to scale peptide synthesizer capacity from 0.5 KL to 6.37 KL. Early-stage biotech projects and molecules nearing commercialization demonstrate strong pipeline momentum.

3. Business Developments:

No new acquisitions. Specialty portfolio includes complex APIs like Paliperidone and Dorzolamide. CMS segment serves 511 active innovator projects, up from 462 last year. Continued filings of DMFs and support for NDA/IND submissions, including the first peptide DMF for Difelikefalin, underline R&D strength.

4. Market Position & Competitive Advantage:

Over 40 years in API manufacturing with presence in 80+ countries and 3 USFDA-inspected plants. Reactor capacity totals 1,174 KL. Diverse portfolio spanning Generics, Specialty, and CMS lends scale and resilience. Strong R&D, especially in high-value molecules and peptides, cements leadership in niche APIs. Recognized ESG and safety credentials enhance reputation.

5. Investor Implications:

Robust free cash flow and aggressive investment in peptide capacity expansion highlight positive growth potential. Margin pressures and revenue softness require monitoring, but shifting focus to Specialty and CMS segments, plus biotech engagement, support a constructive medium-to-long-term view. Execution risk lies in peptide scale-up and converting early-stage projects to commercial wins.